SUPPLEMENT

Q3 2020 — Reconciliation of Non-GAAP Financial Measures

Q3 2020PDF · 6 pages189 KB
Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Dollars in Millions Except Per Share Data) 	2020 	2019 	2020 	2019
Net Earnings, after tax- as reported 	$3,554 	$1,753 	$12,976 	$11,109
Pre-tax Adjustments
Intangible Asset Amortization expense 	1,181 	1,138 	3,426 	3,386
Litigation expense, net 	1,477 	4,000 	2,210 	4,832
IPR&D 	138 	- 	144 	890
Restructuring related 	130 	128 	363 	360
Acquisition and Integration related ¹ 	(154) 	107 	(1,087) 	229
Unrealized (gains)/losses on securities 	32 	89 	(174) 	(217)
Medical Device Regulation 2 	38 	- 	89 	-
Other 	3 	7 	6 	7
Tax Adjustments
Tax impact on special item adjustments 3 	(482) 	(1,159) 	(1,002) 	(1,922)
Tax legislation and related impacts 	(49) 	(391) 	(483) 	(391)
Adjusted Net Earnings, after tax 	$5,868 	$5,672 	$16,468 	$18,283
Average shares outstanding (Diluted) 	2,669.3 	2,669.9 	2,670.8 	2,688.1
Adjusted net earnings per share (Diluted) 	$2.20 	$2.12 	$6.17 	$6.80
Operational adjusted net earnings per share (Diluted) 	$2.17 	$6.18
Notes:
1
2
3
Third Quarter 	Nine Months Ended
Acquisition and integration related costs for 2020 primarily includes a Contingent Consideration reversal ($165M in third
quarter and $1,148M in nine months) related to the timing of certain developmental milestones associated with the Auris
Health acquisition.
European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously
registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and
manufacturers of currently marketed medical devices are required to comply with EU MDR beginning in May 2021. The
Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-
going operations. The Company has excluded only external third-party regulatory and consulting costs from its Medical
Devices operating segments' measures of profit and loss used for making operating decisions and assessing performance.
The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the
above pre-tax special items in arriving at adjusted earnings.

-- 1 of 6 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Consumer Health 	Pharmaceutical 	Medical Devices 	Total
WW As Reported 	1.3% 	5.0% 	(3.6)% 	1.7%
U.S. 	11.6% 	1.5% 	1.2% 	2.7%
International 	(5.6)% 	9.7% 	(8.1)% 	0.6%
WW Currency 	(1.7) 	0.4 	0.3 	0.0
U.S. 	- 	- 	- 	-
International 	(2.9) 	0.9 	0.4 	0.0
WW Operational 	3.0% 	4.6% 	(3.9)% 	1.7%
U.S. 	11.6% 	1.5% 	1.2% 	2.7%
International 	(2.7)% 	8.8% 	(8.5)% 	0.6%
General Surgery
Advanced Sterilization Products 	0.5 	0.2
U.S. 	0.0 	0.0
International 	0.9 	0.4
Baby Care
Baby Center 	0.1 	0.0
U.S. 	0.4 	0.1
International 	0.0 	0.0
All Other Acquisitions and Divestitures 	0.0 	0.1 	0.0 	0.1
U.S. 	0.0 	0.0 	0.1 	0.0
International 	(0.1) 	0.3 	0.0 	0.1
WW Adjusted Operational 	3.1% 	4.7% 	(3.3)% 	2.0%
U.S. 	12.0% 	1.5% 	1.3% 	2.8%
International 	(2.8)% 	9.2% 	(7.6)% 	1.1%
Adjusted Operational Sales Growth
THIRD QUARTER 2020 ACTUAL vs. 2019 ACTUAL
Segments
Note: Percentages are based on actual, non-rounded figures and may not sum

-- 2 of 6 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Consumer Health 	Pharmaceutical 	Medical Devices 	Total
WW As Reported 	1.0% 	5.2% 	(15.3)% 	(2.0)%
U.S. 	11.1% 	5.2% 	(15.1)% 	0.0%
International 	(6.4)% 	5.3% 	(15.5)% 	(4.0)%
WW Currency 	(2.4) 	(0.9) 	(0.7) 	(1.2)
U.S. 	- 	- 	- 	-
International 	(4.2) 	(2.1) 	(1.4) 	(2.3)
WW Operational 	3.4% 	6.1% 	(14.6)% 	(0.8)%
U.S. 	11.1% 	5.2% 	(15.1)% 	0.0%
International 	(2.2)% 	7.4% 	(14.1)% 	(1.7)%
Skin Health / Beauty
Dr. Ci Labo - Japan 	(0.1) 	0.0
U.S. 	0.0 	0.0
International 	(0.2) 	0.0
General Surgery
Advanced Sterilization Products 	0.9 	0.3
U.S. 	0.8 	0.3
International 	0.9 	0.4
Baby Care
Baby Center 	0.2 	0.0
U.S. 	0.6 	0.1
International 	0.0 	0.0
All Other Acquisitions and Divestitures 	(0.1) 	0.2 	0.0 	0.1
U.S. 	0.0 	0.0 	0.0 	0.0
International 	(0.1) 	0.3 	0.0 	0.1
WW Adjusted Operational 	3.4% 	6.3% 	(13.7)% 	(0.4)%
U.S. 	11.7% 	5.2% 	(14.3)% 	0.4%
International 	(2.6)% 	7.7% 	(13.1)% 	(1.3)%
Adjusted Operational Sales Growth
NINE MONTHS 2020 ACTUAL vs. 2019 ACTUAL
Segments
Note: Percentages are based on actual, non-rounded figures and may not sum

-- 3 of 6 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
2020 	2019 	2020 	2019 	2020 	2019 	2020 	2019 	2020 	2019
Reported Income Before Tax by Segment 	$ 	191 	653 	3,439 	(222) 	1,010 	1,392 	(239) 	(176) 	4,401 	1,647
% to Sales 	5.4% 	18.8% 	30.1% 	-2.0% 	16.4% 	21.8% 	-1.1% 	-0.8% 	20.9% 	7.9%
Intangible asset amortization expense 	104 	84 	828 	809 	249 	245 	- 	- 	1,181 	1,138
In-process research and development 	- 	- 	- 	- 	138 	- 	- 	- 	138 	-
Litigation expense, net 	531 	(8) 	971 	3,974 	(25) 	34 	- 	- 	1,477 	4,000
Unrealized loss/(gain) on securities 	(1) 	2 	31 	58 	2 	29 	- 	- 	32 	89
Restructuring related 	31 	17 	29 	24 	70 	87 	- 	- 	130 	128
Acquisition and integration related 	- 	- 	1 	33 	(155) 	74 	- 	- 	(154) 	107
Medical Device Regulation 	- 	- 	- 	- 	38 	- 	- 	- 	38 	-
Other 	- 	- 	- 	- 	3 	7 	- 	- 	3 	7
Adjusted Income Before Tax by Segment 	$ 	856 	748 	5,299 	4,676 	1,330 	1,868 	(239) 	(176) 	7,246 	7,116
% to Sales 	24.4% 	21.6% 	46.4% 	43.0% 	21.6% 	29.3% 	-1.1% 	-0.8% 	34.4% 	34.3%
*Estimated as of 10/13/2020.
Q3 QTD - Income Before Tax by Segment*
Dollars in Millions
Consumer Health 	Pharmaceutical 	Medical Devices 	Unallocated 	Worldwide Total

-- 4 of 6 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
2020 	2019 	2020 	2019 	2020 	2019 	2020 	2019 	2020 	2019
Reported Income Before Tax by Segment 	$ 	993 	1,800 	11,787 	5,786 	2,681 	6,078 	(611) 	(554) 	14,850 	13,110
% to Sales 	9.5% 	17.4% 	35.4% 	18.3% 	16.4% 	31.4% 	-1.0% 	-0.9% 	24.7% 	21.4%
Intangible asset amortization expense 	306 	287 	2,378 	2,370 	742 	729 	- 	- 	3,426 	3,386
In-process research and development 	- 	- 	- 	890 	144 	- 	- 	- 	144 	890
Litigation expense, net 	1,169 	172 	1,006 	4,325 	35 	335 	- 	- 	2,210 	4,832
Unrealized loss/(gain) on securities 	- 	(1) 	(177) 	(236) 	3 	20 	- 	- 	(174) 	(217)
Restructuring related 	69 	61 	70 	68 	224 	231 	- 	- 	363 	360
Acquisition and integration related 	- 	- 	20 	123 	(1,107) 	106 	- 	- 	(1,087) 	229
Medical Device Regulation 	- 	- 	- 	- 	89 	- 	- 	- 	89 	-
Other 	- 	- 	- 	- 	6 	7 	- 	- 	6 	7
Adjusted Income Before Tax by Segment 	$ 	2,537 	2,319 	15,084 	13,326 	2,817 	7,506 	(611) 	(554) 	19,827 	22,597
% to Sales 	24.3% 	22.4% 	45.3% 	42.1% 	17.2% 	38.8% 	-1.0% 	-0.9% 	33.0% 	36.9%
*Estimated as of 10/13/2020.
Q3 YTD - Income Before Tax by Segment*
Dollars in Millions
Consumer Health 	Pharmaceutical 	Medical Devices 	Unallocated 	Worldwide Total

-- 5 of 6 --

Third Quarter 	Third Quarter
Sept. 27, 2020
GAAP
Intangible asset
amortization
Litigation
expense, net
Restructuring
related
Acquisition
related (1)
Medical Device
Regulation 	Other
Sept. 27, 2020
Non-GAAP
Cost of products sold 	6,972	$ 	(1,181) 	(32) 	(18) 	5,741
Selling, marketing and admin expenses 	5,431 	(4) 	5,427
Research and development expense 	2,840 	5 	(16) 	2,829
Other (Income) / Expense 	1,200 	- 	(1,477) 	(30) 	149 	(32) 	(3) 	(193)
In-process research and development 	138 	(138) 	-
Restructuring 	68 	(68) 	-
Provision for taxes on income 	847 	187 	230 	29 	22 	3 	5 	7 	49 	(1) 	1,378
Net Earnings 	3,554 	994 	1,247 	109 	108 	(157) 	27 	31 	(49) 	4 	5,868
Third Quarter 	Third Quarter
Sept. 29, 2019
GAAP
Intangible asset
amortization
Litigation
expense, net
Restructuring
related
Acquisition
related
Medical Device
Regulation 	Other
Sept. 29, 2019
Non-GAAP
Cost of products sold 	6,867	$ 	(1,138) 	(20) 	- 	5,709
Other (Income) / Expense 	4,214 	(4,000) 	(39) 	(107) 	(89) 	(7) 	(28)
Restructuring 	69 	(69) 	-
Provision for/(Benefit from) taxes on income 	(106) 	127 	920 	22 	19 	18 	391 	53 	1,444
Net Earnings 	1,753 	1,011 	3,080 	106 	88 	71 	(391) 	(46) 	5,672
Nine Months 	Nine Months
Sept. 27, 2020
GAAP
Intangible asset
amortization
Litigation
expense, net
Restructuring
related
Acquisition
related (1)
Medical Device
Regulation 	Other
Sept. 27, 2020
Non-GAAP
Cost of products sold 	20,613	$ 	(3,426) 	(69) 	(40) 	17,078
Selling, marketing and admin expenses 	15,627 	(10) 	15,617
Research and development expense 	8,127 	- 	(39) 	8,088
Other (Income) / Expense 	545 	- 	(2,210) 	(107) 	1,087 	174 	(6) 	(517)
In-process research and development 	144 	(144) 	-
Restructuring 	187 	(187) 	-
Provision for taxes on income 	1,874 	550 	373 	30 	65 	10 	(42) 	16 	483 	- 	3,359
Net Earnings 	12,976 	2,876 	1,837 	114 	298 	(1,097) 	(132) 	73 	(483) 	6 	16,468
Nine Months 	Nine Months
Sept. 29, 2019
GAAP
Intangible asset
amortization
Litigation
expense, net
Restructuring
related
Acquisition
related
Medical Device
Regulation 	Other
Sept. 29, 2019
Non-GAAP
Cost of products sold 	20,422	$ 	(3,348) 	(81) 	16,993
Other (Income) / Expense 	2,509 	(38) 	(4,832) 	(117) 	(229) 	217 	(7) 	(2,497)
In-process research and development 	890 	(890) 	-
Restructuring 	162 	(162) 	-
Provision for taxes on income 	2,001 	550 	1,068 	187 	63 	31 	(46) 	391 	69 	4,314
Net Earnings 	11,109 	2,836 	3,764 	703 	297 	198 	(171) 	(391) 	(62) 	18,283
(1) Primarily includes a Contingent Consideration reversal ($165M 2020 quarter to date/$1,148M 2020 year to date) related to the timing of certain developmental milestones associated with the Auris Health acquisition.
In-process
research and
development
Unrealized
(loss)/gain on
securities
Tax legislation and
related impacts
In-process
research and
development
Unrealized
(loss)/gain on
securities
Tax legislation and
related impacts
Year to Date
In-process
research and
development
Unrealized
(loss)/gain on
securities
Tax legislation and
related impacts
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions
Quarter to Date
In-process
research and
development
Unrealized
(loss)/gain on
securities
Tax legislation and
related impacts

-- 6 of 6 --